NASDAQ · SLP
Healthcare · Medical - Healthcare Information Services
$18.50
Up+$0.00 (+0.00%)
Updated Nov 4, 2026, 11:41 PM
SID Score
6.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SLP
1M range · 0 trading sessions · Daily adjusted prices
SLP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SLP.
Company
Market Activity
Research & News
SLP research
Company profile and research snapshot.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 17, 2026 | William Blair | Market Perform | — |
| Apr 10, 2026 | TD Cowen | Hold | — |
| Jan 8, 2026 | TD Cowen | Hold | — |
| Dec 18, 2025 | BTIG | Neutral | — |
| Sep 30, 2025 | TD Cowen | Hold | — |
No generated briefing is available yet.
Yahoo · Oct 6, 2026
RESEARCH TRIANGLE PARK, N.C., October 06, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.
Yahoo · Sep 17, 2026
RESEARCH TRIANGLE PARK, N.C., September 17, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technolog
Benzinga · Sep 17, 2026
Agency will use the software platform to support modern cosmetic safety assessment through integrated exposure and toxicity modeling.Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the
Benzinga · Aug 13, 2026
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLP.
